Roche Holding stock pre-market at EUR 385.60
Published on 10/08/2026 at 08:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock was quoted at EUR 385.60 pre-market by Lang & Schwarz at 8:05 a.m. CEST on October 8, 2026. The bid was EUR 383.85 and the ask was EUR 387.35.
Pre-market quote
The Lang & Schwarz indication places Roche Holding at EUR 385.60 before the Xetra session. The quote was recorded in euros, with a bid of EUR 383.85 and an ask of EUR 387.35. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Roche Holding stock.
Investor calendar
Roche’s investor-relations website lists its third-quarter sales 2026 presentation for October 22, 2026, at 2:00 p.m. CEST in a virtual event. The company also lists a Berenberg Pharma CFO Series event for November 2, 2026, at 3:00 p.m. CET. Both dates are published on Roche’s investor-relations page.
Business indicators
Roche’s investor page states that core earnings per share rose 11 percent at constant exchange rates in 2025, reaching CHF 19.46 on a diluted basis. It also reports that 39 million patients were treated with Roche medicines in 2025 and that 31 billion Roche diagnostic tests were delivered to customers worldwide during the year. The figures are presented by Roche.
Upcoming regulatory date
A Yahoo Finance report dated October 5, 2026, said Roche was awaiting an October 9 FDA decision on Tecentriq for certain patients with colon cancer after surgery. The report described the application as covering treatment for some stage III patients whose tumors have mismatch-repair deficiency or high microsatellite instability. It attributed the supporting study to 712 patients and reported three-year disease-free survival of 86.3 percent for the immunotherapy-containing treatment versus 76.2 percent for the control group. The details were reported by Yahoo Finance.
